Archive | ELN RSS feed for this section

All things to all people: the changing requirements of R&D software

29 Jul

Bioprocess tablet

Research and Development (R&D) organizations are becoming more and more focused on innovation. In doing so, they are increasingly opening up their research infrastructures, forming cross-disciplinary diverse teams. The days of two or three pharmaceutical chemistry scientists sitting together in one room, making project decisions, are long gone. They have now been replaced by multidisciplinary teams, with scientists from varying domains, working together in geographically disparate virtual teams.

Continue Reading »

Push/pull: collaboration across external partners in bioanalysis

21 Jul


As outsourcing becomes more prevalent across scientific domains, and in the bioanalysis sphere in particular, the importance of effective collaboration tools has come to the forefront. More and more companies are turning to external providers to help cut costs and increase speed to market. But what happens to the data when firms enter these types of arrangements?

Continue Reading »

Quality embedded: the convergence of process automation and IT

15 Jul


For many scientific operations, day-to-day processes revolve around running assays, getting results and verifying that everything was completed according to the protocol. The challenge inherent in this has been the retrospective approach to quality control (QC). Today’s forward-thinking bioanalytical (BA) laboratories are starting to shift away from this mentality, looking at how they can embed quality into everything they do.

Continue Reading »

Next-generation informatics – the next step in effective process development

10 Jun


Process development groups face challenges on several fronts: quickly developing and transferring robust processes, constant optimization, cutting down on errors and saving time and money. But with research and development (R&D) spend in many parts of the world hitting a plateau, the pressure is on.

Continue Reading »

Managing IP today

2 Apr

Blue and red fibre optical cables

Drivers such as the expiration of pharmaceutical patents, legal and regulatory reforms, and social and cost pressures have increased the value of intellectual property (IP). At the same time, new collaborative ways of working and the externalization of certain workflows and processes have created IP opportunities and threats; while a shift in emphasis to so-called ‘soft’ IP rights or non-patent IP has changed the way in which companies understand and value IP.

Continue Reading »